In addition, the growth of xenograft tumours with epigenetically silenced BRCA1 was reduced by PARP inhibitor treatment.41, 42 However, in a panel of 39 ovarian cancer cell lines representing all histologic subtypes, as well as in a panel of 21 breast cancer cell lines, methylation of the BRCA1 promoter was not detected.35, 43 Furthermore, according to The Cancer Genome Atlas (TCGA), unlike BRCA1/2 mutations, ovarian cancers with epigenetic silencing of BRCA1 through promoter hypermethylation appear not to respond as favourably to platinum and not to exhibit improved survival. This evidence concerns the gene PARP1 and ovarian carcinoma.